US FDA calls for updated product safety data:
This article was originally published in Clinica
Executive Summary
The FDA has asked for updated safety data on certain products to help it reach decisions on reclassification. The request applies to Class III devices in 15 product areas which were on the market prior to 1976. The agency intends to review whether these should be reclassified as Class II or I devices or be subject to a PMA review. The FDA said manufacturers need to submit their 515(i) information by August 14th and recommended that companies making similar products collaborate on a single document for submission.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.